Pancreatic Cancer Research

ResearcherUniversity Hospitals of ClevelandActive in the last 2 years

Mohamedraed Elshami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9977-0923; OpenAlex author ID A5026619325. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2022: 4 papers · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 10

  1. Cure probabilities of patients with pancreatic ductal adenocarcinoma in the United States: A Surveillance, Epidemiology, and End Results-based analysis. Co-author DOI 10.1016/j.surg.2026.110223↗
  2. Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008↗
  3. To Revise or Not Revise? Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15616-y↗
  4. ASO Author Reflections: Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma and Operative Margin Revision. Co-author DOI 10.1245/s10434-024-15658-2↗
  5. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  6. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  7. Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. Co-author DOI 10.1002/pon.5945↗
  8. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  9. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  10. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lee Mayer Ocuin · 8 shared papers, 2022–2024 · strength 1.67
  2. Jordan Michael Winter · 8 shared papers, 2022–2026 · strength 1.64
  3. John Brian Ammori · 7 shared papers, 2022–2024 · strength 1.22
  4. Jeffrey M. Hardacre · 7 shared papers, 2022–2024 · strength 1.22
  5. Jonathan J. Hue · 6 shared papers, 2022–2024 · strength 0.96
  6. Luke Daniel Rothermel · 5 shared papers, 2022–2023 · strength 0.75
  7. Richard S. Hoehn · 3 shared papers, 2022–2024 · strength 0.53
  8. David Lawrence Bajor · 3 shared papers, 2022–2023 · strength 0.44
  9. Hanna H. Kakish · 2 shared papers, 2022–2024 · strength 0.35
  10. Kavin Sugumar · 2 shared papers, 2022–2023 · strength 0.35
  11. Erryk Katayama · 2 shared papers, 2022 · strength 0.27
  12. Shreya Gupta · 1 shared paper, 2023 · strength 0.18
  13. Sakti Chakrabarti · 1 shared paper, 2023 · strength 0.17
  14. Amit Mahipal · 1 shared paper, 2023 · strength 0.17
  15. Ali Vaziri Gohar · 1 shared paper, 2022 · strength 0.13
  16. Mehrdad Zarei · 1 shared paper, 2022 · strength 0.13
  17. Omid Hajihassani · 1 shared paper, 2022 · strength 0.13
  18. Nathaniel E Davis · 1 shared paper, 2022 · strength 0.13
  19. Sarah Coseo Markt · 1 shared paper, 2022 · strength 0.13
  20. Shaffer R. S. Mok · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.